Pharmaceuticals

Allogeneic T Cell Therapies Market Outlook 2026–2030 Driven By Growth Factors And Projections

April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Allogeneic T Cell Therapies Market From 2026 To 2030?

The market for allogeneic t cell therapies has experienced robust expansion over recent years. Projections indicate its value will increase from $1.26 billion in 2025 to $1.38 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. This historical development is primarily driven by factors such as limitations of autologous therapies, early success of car-t treatments, rising cancer prevalence, advancements in immunotherapy research, and the expansion of hospital-based oncology services.

The allogeneic t cell therapies market is anticipated to show significant expansion in the upcoming years, projected to reach $1.98 billion by 2030, at a compound annual growth rate (CAGR) of 9.4%. This growth during the forecast period is propelled by elements such as the increasing need for cost-effective cell therapies, the broadening scope of oncology pipelines, advancements in donor matching, favorable regulatory environments for cell therapies, and the proliferation of specialty cancer centers. Prominent trends for this period include a transition towards off-the-shelf cell therapies, an uptick in clinical trials within oncology, an intensified focus on scalable cell manufacturing, augmented investment in cell engineering, and the growth of specialized treatment facilities.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp

What Key Drivers Are Fueling The Growth Of The Allogeneic T Cell Therapies Market?

The burgeoning incidence of cancer is anticipated to fuel the expansion of the allogeneic T cell therapies market in the future. Cancer encompasses a range of illnesses defined by the unchecked proliferation and dissemination of atypical cells throughout the body. The surge in cancer diagnoses stems from elements like extended life expectancies, evolving lifestyle habits, environmental pollutants, various infections, hereditary predispositions, and shifts in reproductive behaviors, all of which together elevate the occurrence and discovery of the condition. For individuals afflicted with cancer, allogeneic T cell therapies serve to identify and eradicate cancerous cells through the introduction of genetically modified donor T cells, which are designed to identify distinct tumor antigens. As an illustration, data from May 2024 by the National Cancer Institute, a government body in the US, indicated approximately 18.1 million cancer survivors existed in the United States. This count is predicted to grow to 22.5 million by 2032. Furthermore, by 2040, annual new cancer cases are anticipated to hit 29.9 million, while fatalities linked to cancer are projected to climb to 15.3 million. Consequently, the escalating number of cancer cases acts as a primary impetus for the allogeneic T cell therapies market.

Which Segments Define The Allogeneic T Cell Therapies Market Segment Structure?

The allogeneic t cell therapies market covered in this report is segmented –

1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies

2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types

3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Other Therapeutics Indications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies

2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies

What Emerging Trends Are Seen In The Allogeneic T Cell Therapies Market?

Leading companies in the allogeneic T cell therapies market are prioritizing the creation of advanced products, such as gene-edited donor-derived CAR-T and TCR T cell therapies, to gain a competitive advantage. These gene-edited donor-derived T cell therapies involve immune-effector T cells sourced from healthy donors that are genetically manipulated (e.g., T cell receptor (TCR) and HLA genes knocked out, CAR/TCR constructs inserted, safety switches built-in) to develop universal off-the-shelf products. These products can be manufactured in bulk, cryopreserved, and administered rapidly without requiring patient-specific manufacturing. For instance, in January 2024, Allogene Therapeutics, a US-based cell therapy company, unveiled its 2024 platform vision focused on ALPHA3, which represents the industry’s first pivotal trial of an allogeneic CAR-T programme utilizing gene-editing technologies to eliminate graft-versus-host disease (GvHD) risk and enable swift donor-based delivery. The product’s features include donor-derived T cells modified to remove endogenous TCR and HLA molecules, thus reducing host immune rejection and GvHD, a chimeric antigen receptor targeting a tumor antigen to ensure prompt anti-cancer activity, and a cryopreserved ready-to-infuse format to shorten the time to treatment when compared to autologous therapies.

Who Are The Established Players Within The Allogeneic T Cell Therapies Market?

Major companies operating in the allogeneic t cell therapies market are Allogene Therapeutics Inc., Cellectis SA, Fate Therapeutics Inc., Poseida Therapeutics Inc., Atara Biotherapeutics Inc., Autolus Therapeutics Plc, Adaptimmune Therapeutics Plc, Immatics NV, Medigene AG, Celyad Oncology SA, Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Sangamo Therapeutics Inc., MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Bellicum Pharmaceuticals Inc., Enlivex Therapeutics Ltd., Sorrento Therapeutics Inc.

Get The Full Allogeneic T Cell Therapies Market Report:

https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report

Which Region Has The Greatest Market Share In The Allogeneic T Cell Therapies Market?

North America was the largest region in the allogeneic T cell therapies market in 2025. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Allogeneic T Cell Therapies Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report

Browse Through More Reports Similar to the Global Allogeneic T Cell Therapies Market 2026, By The Business Research Company

Allogeneic Cell Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/allogeneic-cell-therapy-global-market-report

Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report

Cell Therapy Technologies Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795